Monograph

R06AX26 - Fexofenadine

Propably not porphyrinogenic

Rationale

Fexofenadine is not an inducer or an irreversible inhibitor of Cytochrome P450 enzymes. There are no indications of porphyrinogenic effects connected with the pharmacodynamic properties of the drug.

Chemical description

Fexofenadine is a butyrophenone-derivative antihistamine. The drug is the active carboxylic acid metabolite of terfenadine.

Therapeutic characteristics

Fexofenadine is a selective histamine H1-receptor antagonist, and it is used in the symptomatic relief of allergic conditions including seasonal allergic rhinitis. It is administered orally. Fexofenadine is not suspected to have any potentially porphyrinogenic side effects.

Metabolism and pharmacokinetics

Only about 5% of the total dose of fexofenadine is metabolised, mostly by the intestinal mucosa, with 0.5 to 1.5% of the dose undergoing hepatic biotransformation by the cytochrome P450 system. Fexofenadine is a substrate of CYP 3A4 and an inhibitor of CYP 2D6, but is not listed as an inducer or irreversible inhibitor of Cytochome P450 enzymes (Rendic 2002).

IPNet drug reports

Uneventful use reported in 1 patient with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes R06A / R06AX or go back.

References

#	Citation details	PMID
*	Scientific articles
1.	Rendic, S. Summery of information on human CYP enzymes: human P450 metabolism. Drug metabolism reviews 2002; 34(1&2), 83-448.
2.	Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine, a comparative review. Clin Pharmacokinet 2008; 47 (4): 217-230 Devillier P, Roche N et al.	18336052
*	Drug reference publications
3.	Sweetman SC, editor. Martindale: The complete drug reference. Fexofenadine. Pharmaceutical Press 2009.
*	Summary of Product Characteristics
4.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Telfast.

Citation details

PMID

Scientific articles

Rendic, S. Summery of information on human CYP enzymes: human P450 metabolism. Drug metabolism reviews 2002; 34(1&2), 83-448.

Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine, a comparative review. Clin Pharmacokinet 2008; 47 (4): 217-230

Devillier P, Roche N et al.

18336052

Drug reference publications

Sweetman SC, editor. Martindale: The complete drug reference. Fexofenadine. Pharmaceutical Press 2009.

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Telfast.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames